Metabolic Activation Articles & Analysis
9 news found
Creative Enzymes, a global leader in enzyme production, is thrilled to announce the latest addition to their hydrolase product line, the Recombinant S-Adenosyl-L-Homocysteine Hydrolase (SAHH). This announcement underscores its unwavering commitment to enzyme innovation and proven track to offering scientifically advanced products. SAHH, a crucial enzyme involved in the biological methylation ...
Dr. Ali Tinazli's post at the Forbes magazine about "How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis" There has never been more hope or promise in the global effort to eradicate cancer. Confidence in finding lifesaving cures is at an all-time high among medical researchers who work tirelessly for a solution. Astounding ...
Araris Biotech AG, a company pioneering antibody-drug conjugate (ADC)-linker technology, announced today that it has recruited Dr. Bernd Schlereth as Chief Development Officer (CDO). He brings with him more than 20 years of experience in pharmaceutical drug development. Between 2019 and 2021 Dr. Bernd Schlereth worked as Vice President Oncology Research at Molecular Partners AG. From 2013 to ...
Further to the announcement of the exclusive option to license the CORE-NK platform released on 21 November 2022, at the request of the ASX, Chimeric Therapeutics (ASX: CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, provides additional information regarding an exclusive license agreement with Case Western Reserve University (CWRU) for ...
Sydney, Australia - November 23, 2022 - Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that Imperial College London has released additional data related to the F-18 Pivalate (RAD 101) Phase 2a imaging trial in patients with brain metastases. High contrast images (see below) ...
Exclusive global license for CORE NK platform (CHM 0201) executed with Case Western Reserve University in Ohio Initial Phase 1 clinical trial results of the CORE NK platform (CHM 0201) were published demonstrating safety and encouraging activity in blood cancers and solid tumours One patient achieved a complete response that was sustained for over 15 months at time of publication Based on ...
Creative Enzymes, a professional enzyme provider located in New York, USA, is always hammering at researches and trials in order to provide customers with various enzyme services and products as many as possible. With the technical escalation of its enzyme platform, the company is proud to launch fully-developed baking enzyme products that can greatly improve the quality of baked goods. Enzymes ...
Newly completed study aimed to understand the safety and potential benefits of the AOB’s cellular structure without the production of nitric oxide and nitrite. CAMBRIDGE, Mass., Aug. 17, 2021 /PRNewswire/ — AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on inflammatory conditions, has announced the completion of a cosmetic ...
This review paper provides unique insight into liquid biopsies and the field of exosomes in the context of other liquid biopsies such as cfDNA and CTC analysis. The exosome field has gone through a rapid growth phase in parallel with the increasing attention over the potential of liquid biopsies. Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne ...